{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SCLC&page=4",
    "query": {
      "condition": "SCLC",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 4001,
    "total_pages": 401,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SCLC&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SCLC&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T19:45:17.588Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02912949",
      "title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumours Harboring NRG1 Fusion",
        "NSCLC Harboring NRG1 Fusion",
        "Pancreatic Cancer Harboring NRG1 Fusion",
        "NRG1 Fusion"
      ],
      "interventions": [
        {
          "name": "zenocutuzumab (MCLA-128)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Partner Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2015-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912949"
    },
    {
      "nct_id": "NCT02784158",
      "title": "An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Lung Cancer",
        "Advanced Malignancies",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ariad Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Orange, California • Detroit, Michigan",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784158"
    },
    {
      "nct_id": "NCT07563738",
      "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Pancreatic Cancer",
        "NSCLC (Advanced Non-small Cell Lung Cancer)"
      ],
      "interventions": [
        {
          "name": "ODM-212",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab and nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine and nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "sotorasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orion Corporation, Orion Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2026-03-27",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Orange, California • Fort Worth, Texas + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07563738"
    },
    {
      "nct_id": "NCT03302234",
      "title": "Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 568,
      "start_date": "2017-12-14",
      "completion_date": "2022-09-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-26",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Burbank, California • Monterey, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03302234"
    },
    {
      "nct_id": "NCT00019006",
      "title": "Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Colon Cancer",
        "Extensive Stage Small Cell Lung Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Limited Stage Small Cell Lung Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Stage III Non-small Cell Lung Cancer",
        "Stage I Pancreatic Cancer",
        "Stage II Non-small Cell Lung Cancer",
        "Stage IVB Pancreatic Cancer",
        "Stage II Pancreatic Cancer",
        "Stage III Colon Cancer",
        "Stage IVA Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Detox-B adjuvant",
          "type": "DRUG"
        },
        {
          "name": "ras peptide cancer vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1995-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019006"
    },
    {
      "nct_id": "NCT00252889",
      "title": "Doxil Topotecan Doublet Cancer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Topotecan and pegylated doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christiana Care Health Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-05",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 1,
      "location_summary": "Newark, Delaware",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252889"
    },
    {
      "nct_id": "NCT02927340",
      "title": "A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2016-10",
      "completion_date": "2023-05",
      "has_results": false,
      "last_update_posted_date": "2021-03-09",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927340"
    },
    {
      "nct_id": "NCT00132522",
      "title": "EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Carcinoma, Non-small-cell Lung",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EMD 273066",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2005-05",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2013-10-25",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 4,
      "location_summary": "Durate, California • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Durate",
          "state": "California"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132522"
    },
    {
      "nct_id": "NCT00003569",
      "title": "Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Lung Cancer",
        "Neurotoxicity",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "dimesna",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "1998-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Buffalo, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003569"
    },
    {
      "nct_id": "NCT02758054",
      "title": "Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-Small Cell Lung Carcinoma",
        "Compliance Behavior",
        "Prevention Harmful Effects"
      ],
      "interventions": [
        {
          "name": "Patient Navigation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "55 Years to 74 Years"
      },
      "enrollment_count": 447,
      "start_date": "2017-06-16",
      "completion_date": "2020-02-28",
      "has_results": false,
      "last_update_posted_date": "2023-04-06",
      "last_synced_at": "2026-10-23T19:45:17.588Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02758054"
    }
  ]
}